Precision medicine has expanded treatment options across oncology and many other disease areas, yet a significant number of eligible patients still do not receive targeted therapies. In this episode of The Top Line, Kelly Hogan speaks with Diaceutics executives Susanne Munksted and Jordan Clark about the gaps that continue to exist between diagnostic testing, treatment decisions and patient access.
The discussion examines findings from Diaceutics' Practice Gaps research, which found that many patients are lost at multiple points in the care pathway, from testing and interpretation to treatment selection. While testing rates and biomarker awareness have improved, speakers note that diagnostic information is not always translated into clinical action in time to influence treatment decisions.
Listen as Munksted and Clark explore how real-time diagnostic intelligence, improved clinical workflows and better connected healthcare systems could help ensure more patients with a broad range of diseases receive the right therapy at the right time. Listen to the podcast to hear their perspective on the future of diagnostic-driven therapies and how to close the gaps between innovation and impact.